Lilly Study Links Immune and Metabolic Biology in Psoriasis and Obesity
New Phase 3b data on Lilly's Taltz and Zepbound drugs provide insights into the interconnected immune and metabolic biology of patients with psoriasis and obesity.
Eli Lilly and Company has released new exploratory data from its TOGETHER-PsO Phase 3b clinical trial, evaluating the combined use of Taltz and Zepbound in adults with moderate-to-severe plaque psoriasis and obesity or overweight.
The study compared Taltz (ixekizumab), a drug targeting interleukin 17A, with a combination of Taltz and Zepbound (tirzepatide), a weight management medication. The findings were presented at the Fall Clinical Dermatology Conference in Las Vegas.
Results indicated that the combination of Taltz and Zepbound affected a broader range of biomarkers related to both psoriasis disease activity and metabolic processes compared to Taltz used alone. This suggests an immunometabolic link between psoriasis and obesity, a condition affecting a significant portion of psoriasis patients in the U.S.
Lilly stated that these findings support a more comprehensive approach to psoriasis care that also addresses obesity. The combination therapy demonstrated superior skin clearance and clinically meaningful weight reduction as early as Week 12, with safety profiles consistent with the individual medications.